Table 1 Clinical and demographic characteristics
From: Tubular reabsorption and local production of urine hepcidin-25
Variable | Controls (n = 24) | Renal disease (n = 30) | CABG 1–2 hours (n = 8) | CABG 12–24 hours (n = 13) |
|---|---|---|---|---|
Male (%) | 46 | 80 | 88 | 85 |
Age (years) | 39 ± 12 | 43 ± 24 | 65 ± 8 | 66 ± 10 |
Serum albumin (g/l) | n.a. | 34 (24–35) | n.a. | n.a. |
Serum creatinine (μmol/l) | 75 (68–83) | 107 (23–147) | 93 (74–116) | 85 (51–102) |
eGFR (ml/min/1.73 m 2 ) | 84 (77–108) | 57 (34–65) | 73 (58–95) | 85 (17–128) |
Proteinuria (g/d) | n.a. | 4.5 (1.7-9.4) | n.a. | n.a. |
Serum β 2 m (mg/l) | n.a. | 2.9 (2.2-4.6) | 2.1 (1.6-2.9) | 1.8 (1.3-2.5) |
Serum hepcidin-25 (nmol/l) | 4.4 (3.2-5.8) | 3.1 (1.1-5.7) | 4.7 (1.5-7.1) | 14.1 (11.1-17.8) |
Urine β 2 m (nmol/mmol creatinine) | n.a. | 142 (13–863) | 312 (1528–5239) | 66 (21–86) |
Urine hepcidin-25 (nmol/mmol creatinine) | 0.9 (0.4-1.7) | 1.4 (0.3-7.1) | 10.4 (0.8-18.7) | 52.2 (34.0-112.1) |
FE of β 2 m (%) | n.a. | 5.1 (0.7-39.1) | 14.1 (7.1-20.7) | 2.7 (0.8-3.7) |
FE of hepcidin-25 (%) | 1.9 (1.0-3.2) | 8.0 (1.9-20.3) | 21.1 (7.2-23.1) | 33.1 (22.2-52.9) |
Duration of CPB (min) | - | - | 101 (63–147)# | 106 (92–125)# |